Morphological and Cytoskeleton Changes in Cells After EMT

Overview

Journal Sci Rep

Specialty Science

Date 2023 Dec 13

PMID 38092761

Authors

Assel Nurmagambetova

Vadim Mustyatsa

Aleena Saidova

Ivan Vorobjev

Affiliations

Soon will be listed here.

Abstract

Epithelial cells undergoing EMT experience significant alterations at transcriptional and morphological levels. However, changes in the cytoskeleton, especially cytoskeleton dynamics are poorly described. Addressing the question we induced EMT in three cell lines (MCF-7, HaCaT and A-549) and analyzed morphological and cytoskeletal changes there using immunostaining and life cell imaging of cells transfected with microtubule and focal adhesion markers. In all studied cell lines, cell area after EMT increased, MCF-7 and A-549 cells became elongated, while HaCaT cells kept the aspect ratio the same. We next analyzed three components of the cytoskeleton: microtubules, stress fibers and focal adhesions. The following changes were observed after EMT in cultured cells: (i) Organization of microtubules becomes more radial; and the growth rate of microtubule plus ends was accelerated; (ii) Actin stress fibers become co-aligned forming the longitudinal cell axis; and (iii) Focal adhesions had decreased area in all cancer cell lines studied and became more numerous in HaCaT cells. We conclude that among dynamic components of the cytoskeleton, the most significant changes during EMT happen in the regulation of microtubules.

Citing Articles

Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer.

Rinderle C, Baker C, Lagarde C, Nguyen K, Al-Ghadban S, Matossian M Anticancer Drugs. 2024; 36(1):39-48.

PMID: 39671264 PMC: 11634125. DOI: 10.1097/CAD.0000000000001658.

Reformed islets: a long-term primary cell platform for exploring mouse and human islet biology.

Haq N, Toczyska K, Wilson M, Jacobs M, Zhao M, Lei Y Cell Death Discov. 2024; 10(1):480.

PMID: 39580467 PMC: 11585622. DOI: 10.1038/s41420-024-02234-6.

Elevated expression levels of the protein kinase DYRK1B induce mesenchymal features in A549 lung cancer cells.

Sester S, Wilms G, Ahlburg J, Babendreyer A, Becker W BMC Cancer. 2024; 24(1):1341.

PMID: 39482615 PMC: 11529244. DOI: 10.1186/s12885-024-13057-0.

A Comprehensive Review of Protein Biomarkers for Invasive Lung Cancer.

Mezentsev A, Durymanov M, Makarov V Curr Oncol. 2024; 31(9):4818-4854.

PMID: 39329988 PMC: 11431409. DOI: 10.3390/curroncol31090360.

CYLD/HDAC6 signaling regulates the interplay between epithelial-mesenchymal transition and ciliary homeostasis during pulmonary fibrosis.

Ni H, Chen M, Dong D, Zhou Y, Cao Y, Ge R Cell Death Dis. 2024; 15(8):581.

PMID: 39122680 PMC: 11316090. DOI: 10.1038/s41419-024-06972-4.

References

Ribatti D, Tamma R, Annese T . Epithelial-Mesenchymal Transition in Cancer: A Historical Overview. Transl Oncol. 2020; 13(6):100773. PMC: 7182759. DOI: 10.1016/j.tranon.2020.100773. View

Huang Y, Hong W, Wei X . The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022; 15(1):129. PMC: 9461252. DOI: 10.1186/s13045-022-01347-8. View

Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M . Guidelines and definitions for research on epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2020; 21(6):341-352. PMC: 7250738. DOI: 10.1038/s41580-020-0237-9. View

Gandalovicova A, Vomastek T, Rosel D, Brabek J . Cell polarity signaling in the plasticity of cancer cell invasiveness. Oncotarget. 2016; 7(18):25022-49. PMC: 5041887. DOI: 10.18632/oncotarget.7214. View

Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3):178-96. PMC: 4240281. DOI: 10.1038/nrm3758. View

Haslehurst A, Koti M, Dharsee M, Nuin P, Evans K, Geraci J . EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012; 12:91. PMC: 3342883. DOI: 10.1186/1471-2407-12-91. View

Huang Z, Zhang Z, Zhou C, Liu L, Huang C . Epithelial-mesenchymal transition: The history, regulatory mechanism, and cancer therapeutic opportunities. MedComm (2020). 2022; 3(2):e144. PMC: 9115588. DOI: 10.1002/mco2.144. View

Kalluri R, Weinberg R . The basics of epithelial-mesenchymal transition. J Clin Invest. 2009; 119(6):1420-8. PMC: 2689101. DOI: 10.1172/JCI39104. View

Loh C, Chai J, Tang T, Wong W, Sethi G, Shanmugam M . The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells. 2019; 8(10). PMC: 6830116. DOI: 10.3390/cells8101118. View

10.

Datta A, Deng S, Gopal V, Yap K, Halim C, Lye M . Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis. Cancers (Basel). 2021; 13(8). PMC: 8070945. DOI: 10.3390/cancers13081882. View

11.

Peng J, Bera R, Chiou C, Yu M, Chen T, Chen C . Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in mice. Hepatology. 2017; 67(6):2226-2243. DOI: 10.1002/hep.29678. View

12.

Nurnberg A, Kollmannsperger A, Grosse R . Pharmacological inhibition of actin assembly to target tumor cell motility. Rev Physiol Biochem Pharmacol. 2013; 166:23-42. DOI: 10.1007/112_2013_16. View

13.

Bhowmick N, Ghiassi M, Bakin A, Aakre M, Lundquist C, Engel M . Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001; 12(1):27-36. PMC: 30565. DOI: 10.1091/mbc.12.1.27. View

14.

Cho H, Yoo J . Rho activation is required for transforming growth factor-beta-induced epithelial-mesenchymal transition in lens epithelial cells. Cell Biol Int. 2007; 31(10):1225-30. DOI: 10.1016/j.cellbi.2007.04.006. View

15.

Masszi A, Di Ciano C, Sirokmany G, Arthur W, Rotstein O, Wang J . Central role for Rho in TGF-beta1-induced alpha-smooth muscle actin expression during epithelial-mesenchymal transition. Am J Physiol Renal Physiol. 2002; 284(5):F911-24. DOI: 10.1152/ajprenal.00183.2002. View

16.

Yoon H, Dehart J, Murphy J, Lim S . Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2014; 63(2):114-28. PMC: 4305513. DOI: 10.1369/0022155414561498. View

17.

Zheng D, Duan H, Wang S, Xu Q, Gan L, Li J . FAK regulates epithelial‑mesenchymal transition in adenomyosis. Mol Med Rep. 2018; 18(6):5461-5472. PMC: 6236295. DOI: 10.3892/mmr.2018.9600. View

18.

Liao G, Nagasaki T, Gundersen G . Low concentrations of nocodazole interfere with fibroblast locomotion without significantly affecting microtubule level: implications for the role of dynamic microtubules in cell locomotion. J Cell Sci. 1995; 108 ( Pt 11):3473-83. DOI: 10.1242/jcs.108.11.3473. View

19.

Kaverina I, Straube A . Regulation of cell migration by dynamic microtubules. Semin Cell Dev Biol. 2011; 22(9):968-74. PMC: 3256984. DOI: 10.1016/j.semcdb.2011.09.017. View

20.

Schober J, Cain J, Komarova Y, Borisy G . Migration and actin protrusion in melanoma cells are regulated by EB1 protein. Cancer Lett. 2009; 284(1):30-6. DOI: 10.1016/j.canlet.2009.04.007. View